Since early 2010, antibodies targeting CD19 and CD22 have been evaluated in relapsed/refractory (R/R) B-ALL [12–14], leading to the approval of these agents as monotherapy in the salvage setting [15, 16]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.